Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its SYS6036 Injection, a humanized monoclonal antibody drug for cancer immunotherapy, has received approval from China’s National Medical Products Administration to begin clinical trials. This approval marks a significant step for the company in advancing its cancer treatment offerings, potentially enhancing its market position in the oncology sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of therapeutic drugs, particularly in the area of cancer immunotherapy.
Average Trading Volume: 214,665,843
Technical Sentiment Signal: Buy
Current Market Cap: HK$122.4B
See more data about 1093 stock on TipRanks’ Stock Analysis page.